Holen Sie sich die Stockscreener-App
2.73
2.15%
-0.06
Handel nachbörslich:
2.80
0.07
+2.56%
Schlusskurs vom Vortag:
$2.79
Offen:
$2.8
24-Stunden-Volumen:
104.63K
Relative Volume:
0.98
Marktkapitalisierung:
$91.53M
Einnahmen:
$210.00K
Nettoeinkommen (Verlust:
$-10.40M
KGV:
-8.6694
EPS:
-0.3149
Netto-Cashflow:
$-6.88M
1W Leistung:
+2.25%
1M Leistung:
-10.49%
6M Leistung:
-41.16%
1J Leistung:
+9.20%
1-Tages-Spanne:
$2.72
$2.80
1-Wochen-Bereich:
$2.65
$2.82
52-Wochen-Spanne:
$2.44
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
Firmenname
Anixa Biosciences Inc
Sektor
Branche
Telefon
408-708-9808
Adresse
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.73 | 93.54M | 210.00K | -10.40M | -6.88M | -0.3149 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-21 | Eingeleitet | Maxim Group | Buy |
| 2022-12-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-04-12 | Eingeleitet | H.C. Wainwright | Buy |
Anixa Biosciences Inc Aktie (ANIX) Neueste Nachrichten
Anixa Biosciences Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
ANIX Stock Price, Quote & Chart | ANIXA BIOSCIENCES INC (NASDAQ:ANIX) - ChartMill
Anixa Biosciences Issues Correction to May 11, 2026 Announcement, Details Available on StockTitan.net - geneonline.com
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-Cel Ovarian Cancer Car-T Therapy - marketscreener.com
Anixa Biosciences (ANIX) Reports Promising Survival Data from Cl - GuruFocus
Anixa reports survival data from ovarian cancer therapy trial - Investing.com UK
/C O R R E C T I O N -- Anixa Biosciences, Inc./ - PR Newswire
Anixa reports survival data from ovarian cancer therapy trial By Investing.com - Investing.com Australia
Anixa Biosciences Reports Updated Positive Survival Observations From Ongoing Phase 1 Trial Of Lira-Cel Ovarian Cancer CAR-T Therapy - TradingView
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy - StreetInsider
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer - Quantisnow
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat - Quantisnow
Anixa Biosciences (NASDAQ:ANIX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - The Malaysian Reserve
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV - Investing News Network
Bloomberg TV to air Anixa CEO on cancer vaccine and CAR-T data - Stock Titan
Anixia Biosciences and OwlTing Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ChartMill
Anixa Biosciences CEO to discuss positive breast cancer vaccine and ovarian cancer therapy data on Bloomberg TV. - Pluang
Anixa Biosciences announces issuance of Mexican patent covering breast cancer vaccine technology - marketscreener.com
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology - The AI Journal
Anixa Biosciences (ANIX) Secures Patent for Breast Cancer Vaccine Technology - GuruFocus
Anixa Biosciences receives Mexican patent for breast cancer vaccine By Investing.com - Investing.com Australia
Anixa Biosciences receives Mexican patent for breast cancer vaccine - Investing.com
A breast cancer vaccine gained patent protection in Mexico until 2040 - Stock Titan
Anixa’s ovarian cancer therapy to be presented at ISCT meeting By Investing.com - Investing.com India
Anixa’s ovarian cancer therapy to be presented at ISCT meeting - Investing.com
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting - Nasdaq
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress - WFXG
Anixa Biosciences Highlights Lean Cash Burn, CAR-T Survival Signals, and Phase II Vaccine Plan at Conference - Yahoo Finance
Weekly Trades: Does Anixa Biosciences Inc have declining or rising EPS2026 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
Aug Macro: Can Anixa Biosciences Inc maintain its current growth rate2026 Analyst Calls & Consistent Profit Trade Alerts - baoquankhu1.vn
AVAX Technologies and Anixa Biosciences Compared in Critical Analysis - National Today
Earnings Risk: Does Anixa Biosciences Inc have declining or rising EPSWeekly Trend Recap & Daily Growth Stock Investment Tips - baoquankhu1.vn
Anixa Biosciences to Participate in RedChip's Biotech Resurgence - GuruFocus
Anixa Biosciences Reports Positive Clinical Trial Results for Cancer Vaccines - Intellectia AI
Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026 - Finviz
At April 16 event, Anixa will spotlight 74% immune response data - Stock Titan
Anixa Biosciences Price Target Maintained With a $10.00/Share by D. Boral Capital - Moomoo
ANIX Stock: Consistent 'Buy' Rating and Price Target Maintained - GuruFocus
Anixa Biosciences' (ANIX) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026 - GuruFocus
Anixa Biosciences to Present at Water Tower Research Insights Conference - National Today
74% vaccine response, CAR-T survival data on Anixa's April 14 agenda - Stock Titan
Breast cancer vaccine hit Phase 1 goals; Anixa cites CAR-T survival data - Stock Titan
Finanzdaten der Anixa Biosciences Inc-Aktie (ANIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anixa Biosciences Inc-Aktie (ANIX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Titterton Lewis H jr | Director |
Dec 15 '25 |
Option Exercise |
2.92 |
16,000 |
46,720 |
969,334 |
| KUMAR AMIT | Chief Executive Officer |
Oct 30 '25 |
Option Exercise |
2.92 |
200,000 |
584,000 |
779,925 |
| Titterton Lewis H jr | Director |
Jul 31 '25 |
Buy |
3.08 |
10,000 |
30,800 |
953,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 30 '25 |
Buy |
3.16 |
5,000 |
15,800 |
579,925 |
| Baskies Arnold M | Director |
Jul 18 '25 |
Buy |
3.39 |
5,000 |
16,950 |
125,000 |
| Titterton Lewis H jr | Director |
Jul 11 '25 |
Buy |
3.14 |
10,000 |
31,400 |
943,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 11 '25 |
Buy |
3.15 |
5,000 |
15,750 |
574,925 |
| KUMAR AMIT | Chief Executive Officer |
Jun 04 '25 |
Buy |
2.85 |
10,000 |
28,500 |
569,925 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):